AbbVie (ABBV), adMare BioInnovations Name RIME Therapeutics as Biotech Innovators Award Winner

AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for the next 15 years. On April 30, AbbVie, in partnership with adMare BioInnovations, named RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award. This national competition is designed to support Quebec’s life sciences sector by supporting early-stage companies that align with AbbVie’s core therapeutic areas, such as immunology and oncology.

RIME Therapeutics was selected for its innovative “Disruptide” platform, which targets complex protein-protein interactions to accelerate drug discovery for inflammatory and immunological diseases. As part of the award, RIME Therapeutics will receive one year of laboratory and office space at the adMare Innovation Centre in Montreal, providing the startup with essential infrastructure and shared technical equipment.

AbbVie (ABBV), adMare BioInnovations Name RIME Therapeutics as Biotech Innovators Award Winner

Beyond physical space, the company will benefit from direct mentorship and expertise from AbbVie Inc.’s (NYSE:ABBV) scientific and business leadership. This collaboration is intended to help the startup transition its research from novel biological concepts into tractable chemical therapies more efficiently. Leadership from all three organizations emphasized the importance of fostering a collaborative ecosystem to scale Canadian life sciences companies globally.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.